Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-15 · accession 0001714899-24-000122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2024-05-15 | DNLI | SATO VICKI L | Dir | S - Sale | $20.39 | -1,674 | 116.4K | -1% | -$34.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-15 | S | D | 1,674 | $20.39 | 116,369 | D | — | — | (F2) Includes 4,216 unvested RSUs. |